Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy of dexfenfluramine in the treatment of alcohol dependence
Autore:
Romach, MK; Sellers, EM; Kaplan, HL; Somer, GR; Gomez-Mancilla, B;
Indirizzi:
Sunnybrook & Womens Coll Hlth Sci Ctr, Ctr Res Womens Hlth, Psychopharmacol & Dependence Res Unit, Toronto, ON M5S 1B2, Canada Sunnybrook & Womens Coll Hlth Sci Ctr Toronto ON Canada M5S 1B2 2, Canada Ctr Addict & Mental Hlth, Toronto, ON, Canada Ctr Addict & Mental Hlth Toronto ON Canada tal Hlth, Toronto, ON, Canada
Titolo Testata:
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
fascicolo: 10, volume: 24, anno: 2000,
pagine: 1534 - 1541
SICI:
0145-6008(200010)24:10<1534:EODITT>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; HYPERICUM-PERFORATUM; DOUBLE-BLIND; ANTIDEPRESSANT ACTIVITY; CONSUMMATORY BEHAVIORS; DEPRESSED ALCOHOLICS; ABSTINENT ALCOHOLICS; RELAPSE PREVENTION; MAJOR DEPRESSION; PREFERRING RATS;
Keywords:
alcohol; serotonin; dexfenfluramine; comorbidity; combination therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Romach, MK Sunnybrook & Womens Coll Hlth Sci Ctr, Ctr Res Womens Hlth, Psychopharmacol & Dependence Res Unit, Womens Coll Campus,76 Grenville St, Toronto, ON M5S 1B2, Canada Sunnybrook & Womens Coll Hlth Sci Ctr Womens Coll Campus,76 Grenville St Toronto ON Canada M5S 1B2
Citazione:
M.K. Romach et al., "Efficacy of dexfenfluramine in the treatment of alcohol dependence", ALC CLIN EX, 24(10), 2000, pp. 1534-1541

Abstract

Background: A substantial body of evidence supports a role for serotonin in modulating alcohol intake, which suggests that this neurotransmitter represents a promising target for pharmacotherapy development for alcohol use disorders. Dexfenfluramine, a serotonin releaser and reuptake inhibitor, decreases alcohol self-administration by rats. Its greater potency and severalmechanisms of action suggest it should be mere effective in treating alcohol dependence than drags that only inhibit serotonin reuptake. Methods: We conducted an 11 week, randomized, double-blind trial that compared oral placebo and dexfenfluramine 7.5, 15, 22.5, and 30 mg bid in 136 alcohol-dependent patients. A brief behavioral intervention was offered concurrently. Results: The majority of subjects were male (72%), and the age of the group was 44 +/- 11 years (mean +/- SD). Both placebo- and drug-treated groups significantly reduced alcohol consumption compared with baseline (a 55% decrease in mean drinks per day: p < 0.01), but there were no significant differences between drug and placebo groups or dose effects for most outcome measures. Conclusions: Our results with dexfenfluramine are further evidence that serotonergic medications on their own do not significantly reduce alcohol consumption in alcohol-dependent individuals. Combination pharmacotherapy withagents that act on different receptors or neurotransmitter systems (e.g., naltrexone plus dexfenfluramine) may be one way to enhance serotonergic effects on drinking behavior and should be considered in future medication development clinical trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 03:36:53